Perceptive Advisors, a major life-sciences investment firm, significantly cut its position in Guardant Health (GH) by 86.2%, an estimated $38.81 million trade. According to its latest quarterly disclosure with the SEC, the firm's holding was reduced from 300,000 to just over 41,000 shares. Investors are reminded that 13F filings are delayed and reflect trading activity that occurred during the second quarter, which ended June 30, 2026.
This portfolio adjustment by Perceptive Advisors preceded Guardant Health's strong second-quarter financial report on July 30, 2026. In that report, Guardant Health announced a 44% year-over-year revenue increase and raised its full-year guidance, driven by the rapid adoption of its Shield cancer screening test. [1, 5, 7] Following the positive results, multiple analysts raised their price targets for the company's stock. [9, 15]